Apr 08, 2019 11:43 JST

Source: Eisai

Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Start Your Day With a Sparkling Pop!

Containing 75 Lemons Worth of Vitamin C and 50% Less Calories!

TOKYO, Apr 08, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims, in Japan on Tuesday, April 9.

Chocola BB Sparkling Kiwi & Lemon Flavor is a new carbonated beverage classified by the Japanese Consumer Affairs Agency as a Food with Nutrient Function Claims (Niacin), and is the newest product flavor of the Chocola BB Sparkling series which has been well received mainly by working women since the series? initial launch in 2011. The drink contains five ingredients that help bring out women?s beauty from within, including 1500 mg of vitamin C which is equivalent to 75 lemons, in addition to vitamin B1, B6, iron, as well as niacin to help maintain the health of skin and mucosal membranes. Compared to the original Chocola BB Sparkling Grapefruit & Peach Flavor, calories have been reduced by 50% (24kcal).

By adding the new Chocola BB Sparkling Kiwi & Lemon Flavor with its fresh taste to the Chocola BB Sparkling lineup, consumers will be able to enjoy a choice between two flavors to match their personal needs for refreshment.

Eisai continues to provide the Chocola BB family of products to respond to the diverse needs of women and support a greater number of people to achieve health and beauty in their everyday lives.

 


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
April 18 2024 09:53 JST
 
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
April 17 2024 15:17 JST
 
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
April 03 2024 15:24 JST
 
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
April 01 2024 08:39 JST
 
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
March 29 2024 14:51 JST
 
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
March 29 2024 14:19 JST
 
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 13:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
More Press release >>

Latest Press Release


More Latest Release >>